Hims & Hers Health (HIMS) stock rose over 45% in the last month, with its trading price reaching $36.07. This increase comes alongside Bank of America (BofA) raising its price target for the stock to $37, up from a previous target of $36, while maintaining a Neutral rating due to concerns over valuation.

BofA analyst Allen Lutz has indicated that the month-over-month customer growth for oral Wegovy has stagnated, based on credit and debit card data. The report highlights that customer retention could be weak as initial subscription fees of $39 may lead to a drop-off when costs escalate to $149 in the second month. The findings reflect a worrying trend that could undermine Hims’ projected earnings growth for the latter half of the year.

Why This Matters

The surge in stock price coincides with Hims' strategic expansion and product diversification, which may have implications for market positioning and investor sentiment. Key factors include:

  • BofA's raised valuation multiple from 33.5x to 34.5x CY26 EV/EBITDA.
  • Short interest exceeding 28% of the float indicates ongoing skepticism from investors.
  • The stock reflects a Wall Street consensus of Moderate Buy, with a price target averaging $30.14, suggesting about a 16% potential downside.

While the stock has gained traction, the analyst cautiousness suggests that continued growth may face headwinds. Hims has recently pivoted towards expanding its offerings outside the United States after acquiring Eucalyptus, which supports the weight loss platform Juniper and extends its reach into countries such as Germany, Japan, Australia, the UK, and Canada.

Future Considerations

The company is adapting to market dynamics by rolling out new products such as the “Labs AI” clinical agent and testosterone therapy pills. However, analysts highlight that competitor Ro has experienced a decline in new customer growth, which Hims might replicate.

Additionally, regulatory changes surrounding therapeutic peptides could strengthen Hims’ position, as management anticipates significant revenue growth targets for 2030. Observers will be keenly watching upcoming earnings reports to gauge the sustainability of Hims’ stock performance amid mixed signals from the market.

This material is for informational purposes only and does not constitute financial advice.